ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1958

Patterns and Impact of Long-term Glucocorticoid Use on RA Patients at Risk for Major Adverse Cardiac Events

Beth Wallace1, Yuqing Gao2, Punyasha Roul3, Bryant England3, Ted Mikuls3, Shirley Cohen-Mekelburg4, Daniel Clauw5, Rodney Hayward1 and Akbar Waljee1, 1Michigan Medicine, VA Ann Arbor Healthcare System Center for Clinical Management Research, Ann Arbor, MI, 2VA Ann Arbor Healthcare System, Center for Clinical Management Research, Ann Arbor, MI, 3University of Nebraska Medical Center, Omaha, NE, 4Michigan Medicine/VA Ann Arbor Healthcare System Center for Clinical Management Research, Ann Arbor, MI, 5Michigan Medicine, Ann Arbor, MI

Meeting: ACR Convergence 2020

Keywords: glucocorticoids, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: Health Services Research (1958–1962)

Session Type: Abstract Session

Session Time: 10:00AM-10:50AM

Background/Purpose: One-quarter to one-third of RA patients use long-term glucocorticoids (GCs) despite their known, dose-dependent association with increased risk of major adverse cardiovascular (CV) events (MACE). Little is known about patterns of GC use among RA patients with MACE risk factors (e.g. diabetes, smoking), or how GC use may potentiate these risk factors.

Methods: In this retrospective cohort study, we used administrative data to identify 6,090 RA patients with ≥1 visit to Veterans Health Administration rheumatology clinic during 2013-2017. We excluded patients with no disease-modifying anti-rheumatic drug use (n = 686) and confounding disorders also treated with GCs (n = 2,520). In the resulting 2,884-patient cohort, we used logistic regression to evaluate associations between incident MACE during 2013-2018 (outcome), recent long-term GC use (predictor), and baseline MACE risk factors (covariates). We included 5 MACE risk factors: hypertension, diabetes, hyperlipidemia, tobacco use, and prior MACE. To examine how GC use influences the effects of MACE risk factors, we included two-way interaction terms between GC use and each of the five MACE risk factors defined above.

We used a validated claims-based algorithm to define MACE as any of acute myocardial infarction, ischemic stroke, transient ischemic attack, sudden death, or coronary revascularization, occurring between index date and December 31, 2018. Index date was defined as the patient’s first rheumatology visit after meeting RA diagnostic criteria. We defined recent long-term GC use as ≥90 days’ supply dispensed during the two years preceding index date.  

Results: Among 2,884 RA patients, 1,553 (54%) had MACE risk factors, and 97 (3%) had prior MACE (Table 1). Overall, 16% of patients recently used long-term GC, compared to 17% of patients with MACE risk factors, and 22% of patients with prior MACE. Incident MACE occurred in 308 (11%) patients, 24% of whom had recent long-term GC use. Recent long-term GC use was independently associated with increased incident MACE (Table 2). While no interaction term was statistically significant overall, differences in odds of incident MACE were seen across levels of recent GC use for several risk factors, particularly diabetes (OR 2.10, 95% CI [0.93-4.77]), tobacco use (OR 2.88, 95% CI [1.16-7.14]) and prior MACE (OR 2.41, 95% CI [0.73-7.95]) (Table 3).

Conclusion: Long-term GC use is common among RA patients with MACE risk factors, including those with prior MACE. In this cohort, a quarter of patients with an incident MACE had recently used long-term GC. Long-term GC use may potentiate the effect of comorbidities like diabetes and tobacco use, disproportionately increasing MACE risk in certain patients. Further work is needed to evaluate the effect of persistent long-term GC use after MACE events, and to explore how GC use may amplify the effects of other CV risk factors.

Table 1: Baseline characteristics by risk of MACE, assessed at first VA rheumatologist visit during the study period.

Table 2: Multivariable logistic regression model showing association between long-term GC use in the 2 years prior to index date and incident MACE.

Table 3: Odds ratios for two-way interactions between long-term GC use and five MACE risk factors.


Disclosure: B. Wallace, None; Y. Gao, None; P. Roul, None; B. England, None; T. Mikuls, Horizon Therapeutics, 2; S. Cohen-Mekelburg, None; D. Clauw, Pfizer, 1, 2, Tonix, 1, Aptinyx, 1, 2, Daiichi Sankyo, 1, Samumed, 1, Intec Pharma, 1, Eli Lilly, 1, Zynerba, 1, Williams & Connolly LLP, 1, Nix Patterson LLP, 1, Theravance, 1; R. Hayward, None; A. Waljee, None.

To cite this abstract in AMA style:

Wallace B, Gao Y, Roul P, England B, Mikuls T, Cohen-Mekelburg S, Clauw D, Hayward R, Waljee A. Patterns and Impact of Long-term Glucocorticoid Use on RA Patients at Risk for Major Adverse Cardiac Events [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/patterns-and-impact-of-long-term-glucocorticoid-use-on-ra-patients-at-risk-for-major-adverse-cardiac-events/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patterns-and-impact-of-long-term-glucocorticoid-use-on-ra-patients-at-risk-for-major-adverse-cardiac-events/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology